Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATRICIA: Efficacy of HPV-16/18 AS04 Vaccine
NCT00122681Phase 3Completed
- Sponsor
- GSK
- Start
- May 2004
- Primary completion
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by GSK. Primary endpoint: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection at Month 48. Started May 2004; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00122681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122681.